About
Specialty, Generics, Consumer Products, Contract Manufacturing
Areas of Focus
Categories
Small Molecule PharmaceuticalGeneric DrugJapan
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
12
As Collaborator
4
Total Enrollment
2,494
By Phase
PHASE3: 5PHASE2: 2PHASE4: 1PHASE1: 7
By Status
COMPLETED: 14RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05905055Lead Sponsor
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
PHASE3Recruiting
150 participants
Started: Sep 22, 2023 · Completed: Sep 30, 2025
NCT05887908Lead Sponsor
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
PHASE3Completed
614 participants
Started: May 23, 2023 · Completed: Nov 26, 2024
NCT05268016Lead Sponsor
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
PHASE2Completed
132 participants
Started: Mar 24, 2022 · Completed: May 31, 2023
NCT04785326Collaborator
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
PHASE3Completed
598 participants
Started: Apr 28, 2021 · Completed: Nov 16, 2022
NCT04709172Lead Sponsor
Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
PHASE4Completed
20 participants
Started: Jan 5, 2021 · Completed: Aug 15, 2021
Locations (1)
Headquarters
Tokyo, Japan
Map
Loading map...